Detecting new lesion formation in multiple sclerosis: The relative contributions of monthly dual-echo and T1-weighted scans after triple-dose gadolinium

European Neurology

Volumn 40, Issue 3, 1998, Pages 146-150

  Filippi, M ^a,d   Mastronardo, G ^a   Rocca, M A ^a   Capra, R ^b   Gasperini, C ^c   Rovaris, M ^a   Bastianello, S ^c   Comi, G ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Dual echo; Gadolinium DTPA; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

GADOLINIUM; GADOLINIUM PENTETATE;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; IMAGE ENHANCEMENT; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; BRAIN; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RADIOPHARMACEUTICALS;

EID: 0031696806     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007971     Document Type: Article

References (17)

1. Miller DH, Barkhof F, Nauta JJP: Gadolinium enhancement increased the sensitivity of MRI in detecting disease activity in MS. Brain 1993; 116:1077-1094.
2. Filippi M, Yousry T, Campi A, Kandziora C, Colombo B, Voltz R, Martinelli V, Spuler S, Bressi S, Scotti G, Comi G: Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology 1996;46:379-384.
3. Silver NC, Good CD, Barker GJ, MacManus DG, Thompson AJ, Moseley IF, McDonald WI, Miller DH: Sensitivity of contrast enhanced MRI in multiple sclerosis: Effects of gadolinium dose, magnetisation transfer contrast and delayed imaging. Brain 1997;120: 1149-1161.
4. Van Waesberghe JHTM, Catelijns JA, Roser W, Silver N, Yousry T, Lyklama à Nijeholt, Ader HJ, Uitdehaag BMJ, Radue EW, Polman CH, Kappos L, Miller DH, Barkhof F: Single dose gadolinium with magnetization transfer contrast versus triple dose gadolinium in detecting enhancing multiple sclerosis lesions. Am J Neuroradiol 1997;18:1279-1285.
5. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227-231.
6. Lublin FD, Reingold SC. the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis: Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907-911.
7. Miller DH, Barkhof F, Berry I, Kappos L, Scotti G, Thompson AJ: Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: Concerted Action Guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
8. Filippi M, Horsfield MA, Morrissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH: Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
9. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995; 45:1277-1285.
10. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H, McFarland HF: Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869.
11. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weinstock-Guttman B, Whitman RH, The Multiple Sclerosis Collaborative Research Group: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
12. Miller DH: Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 1994;36:S91-S94.
13. Filippi M, Rossi P, Campi A, Colombo B, Pereira C, Comi G: Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR 1997;18:1549-1556.
14. Lai M, Hodgson T, Gawne-Cain M, Webb S, MacManus DG, McDonald WI, Thompson AJ, Miller DH: A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 60:339-341.
15. McDonald WI, Miller DH, Barnes D: The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992;18:319-334.
16. Filippi M, Rocca MA, Rizzo G, Horsfield MA, Rovaris M, Minicucci L, Colombo B, Comi G: Magnetization transfer ratios in MS lesions enhancing after different doses of gadolinium. Neurology 1998; in press.
17. Filippi M, Yousry T, Baratti C, Horsfield MA, Mammi S, Becker C, Voltz R, Spuler S, Campi A, Reiser MF, Comi G: Quantitative assessment of MRI lesion load in multiple sclerosis: A comparison of conventional spin-echo with fast-fluid attenuated inversion recovery. Brain 1996;119:1349-1355.